March 5, 2018 / 1:08 PM / 3 months ago

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

March 5 (Reuters) - Dermira Inc:

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

* DERMIRA INC - COMPANY EXPECTS TO DISCONTINUE PROGRAM

* DERMIRA - NONE OF THE CO-PRIMARY ENDPOINT RESULTS WERE STATISTICALLY SIGNIFICANT

* DERMIRA - ‍ TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS AGES 9 YRS AND OLDER ​WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

* DERMIRA INC - ‍NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED, AND NO NEW OR UNEXPECTED EVENTS WERE OBSERVED​

* DERMIRA - ‍CONSISTENT WITH PHASE 2A,2B STUDIES, OLUMACOSTAT GLASARETIL WAS WELL-TOLERATED WITH ADVERSE EVENTS PRIMARILY MILD OR MODERATE IN SEVERITY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below